Heme Malignancy Clinical Trials

With an emphasis on transdisciplinary translational research, the OSUCCC-James facilitates investigator-initiated early phase clinical trials and participates in many cooperative groups.

Protocol No.PITitle
CALGB-20802Leslie AndritsosEmbedded Protocol to CALGB-100701
OSU-12194Leslie AndritsosClinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia
AMC-075Robert BaiocchiA Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma
CALGB-8461Clara BloomfieldCytogenetic Studies in Acute Leukemia [Dr. Clara Bloomfield, National Study Chair]
CALGB-60405Kristie BlumEmbedded companion to CALGB 50303: Pharmacogenomics in CALGB 50303.
OSU-10049Kristie BlumA Phase 1/II trial of panobinostat and lenalidomide in patients with relasped or refractory Hodgkin's Lymphoma
CALGB-50801Kristie BlumPhase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma
CALGB-150805Kristie BlumEmbedded Companion Study to CALGB-50604
CALGB-150903Kristie BlumEmbedded Companion study to CALGB-50801
CALGB-150913Kristie BlumEmbedded companion to CALGB-50803
CALGB-580603Kristie BlumEmbedded Companion to CALGB-50303: Evaluating the Prognostic Utility of PET Scanning in Lymphoma
CALGB-50904Kristie BlumRANDOMIZED PHASE II TRIAL OF OFATUMUMAB AND BENDAMUSTINE VS. OFATUMUMAB, BORTEZOMIB (NSC #681239, IND #58443) AND BENDAMUSTINE IN PATIENTS WITH UNTREATED FOLLICULAR LYMPHOMA
OSU-11015Kristie BlumA Phase I/II Study of Gemcitabine and Bendamustine in Patients with Relapsed or Refractory Hodgkin's Lymphoma
CALGB-151005Kristie BlumEmbedded Companion to CALGB-50904
OSU-13131Kristie BlumA Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma
OSU-12106Kristie BlumA Phase II Study of MLN8237 Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
ECOG-E1411Kristie BlumIntergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ¨ R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV¨ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ¨ LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ¨ LR) .
OSU-13016Kristie BlumA Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
CALGB-20703William BlumEmbedded Companion Study to CALGB-10502
OSU-12006William BlumA Phase I, open, cohort dose escalation trial with BI 836858 in patients with refractory or relapsed acute myeloid leukemia
CALGB-20602William BlumEmbedded companion to CALGB 10503;Correlative science in CALGB 10503
CALGB-70603John ByrdEmbedded Campanion Study to CALGB-10501
CALGB-20601John ByrdEmbeded Companion Study to CALGB-10501
CALGB-20702John ByrdEmbeded Campion Study to CALGB-10404
OSU-05099John ByrdNormal Spleen and Tonsil Tissue for Research Use.
OSU-05128John ByrdUse of Red Cross Leukopacs as Source of Normal Human Cells for Research Use.
OSU-0017John ByrdChronic Lymphocytic Leukemia Research Consortium Human Subjects Protocol for Sample Collection
OSU-13018John ByrdA Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
OSU-13225John ByrdA Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia
OSU-13187John ByrdAn Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
OSU-05019Michael CaligiuriAssessment of Aberrant Expression of Leukemic Markers in Normal CD34+ Hematopoietic Precursors.
OSU-T9802Michael CaligiuriThe Arthur G. James Cancer Center, Hematologic Malignancy Tissue Storage Facility
OSU-05061Michael CaligiuriMolecular Studies in Acute Myeloid Leukemia
OSU-08191Michael CaligiuriImmunologic Studies in Hematological Malignancies: Mechanisms of Action in Natural Killer Cell Targeting of Acute Leukemias
OSU-05049Spero CatalandConcurrent Cyclosporine and Plasma Exchange Therapy as Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP)
OSU-05050Spero CatalandStandardized Therapy of Thrombotic Thrombocytopenic Purpura
CALGB-150910Beth ChristianEmbedded Companion to CALGB-50901
OSU-13190Beth ChristianA Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab,Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
OSU-13004Beth ChristianA Phase I Dose Escalation Study of Immunotherapy with IMMU-114 in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
OSU-13022Beth ChristianA Phase I Study of Ibrutinib (PCI-32765) in Combination with Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
OSU-13281Beth ChristianThe Ohio State University - James Cancer Hospital Lymphoma Database
OSU-07087Albert de la ChapelleCharacterization of Potential Susceptibility Genes in Chronic Lymphocytic Leukemia (CLL)
OSU-05041Albert de la ChapelleGenetic Ancestry and its Implications in Cytogenetic and Molecular Abnormalities of Acute Myeloid Leukemia.
OSU-0241Steve DevineProtocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation (A National Marrow Donor Program Protocol).
OSU-0242Steve DevineA Research Database for Hematopoietic Cell Transplantation and Cellular Therapies (A National Marrow Donor Program Protocol).
CALGB-151001Steve DevineEmbedded Companion Study to CALGB-100801
CALGB-60402Steve DevineEmbedded companion to CALGB 100103: Busulfan Pharmacokinetics in Elderly Leukemic Patients in CALGB 100103
OSU-11087Steve DevineA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
OSU-12213Steve DevineA Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies
OSU-13248Yvonne EfeberaMichigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository
ALLIANCE-A061202Yvonne EfeberaA PHASE I/II STUDY OF POMALIDOMIDE, DEXAMETHASONE AND IXAZOMIB VS. POMALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA REFRACTORY TO LENALIDOMIDE AND PROTEASOME INHIBITOR-BASED THERAPY
OSU-13168Yvonne EfeberaPhase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)
OSU-13128Yvonne EfeberaPhase I/II Study of Lenalidomide in Combination with Anti-PD-1 monoclonal antibody CT-011 in Patients with Relapsed/Refractory Multiple Myeloma
OSU-14069Yvonne EfeberaA Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.
BMT-CTN1203Yvonne EfeberaA Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
OSU-11002Yvonne EfeberaAssessment of MicroRNA Expression in Acute Graft-versus-Host Disease
OSU-11052Yvonne EfeberaA Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
OSU-12062Ramiro GarzonA Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies
OSU-13182Ramiro GarzonPhase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia
OSU-12214Michael GreverA Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia
OSU-13020Craig HofmeisterA Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
OSU-14031Craig HofmeisterPilot trial evaluating viral protein production from the combination of Reolysin and Carfilzomib in Multiple Myeloma
OSU-13192Craig HofmeisterA Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib with or without ARRY-520 in Patients with Advanced Multiple Myeloma
OSU-11048Craig HofmeisterA Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies
OSU-10115Craig HofmeisterBuckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
OSU-07012Craig HofmeisterRetrospective Case-Control Study of the Effect of Statin use on Clinical Response to Autologous Stem Cell Transplantation in Myeloma Patients.
OSU-11163Samantha JaglowskiA Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma
OSU-13135Samantha JaglowskiComprehensive Frailty Assessment
OSU-12162Samantha JaglowskiA Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies
OSU-12207Samantha JaglowskiPROJECT BUCKiPAD: THE EVALUATION OF AN iPAD DISTRIBUTION PROGRAM ON ANXIETY AND DEPRESSION IN BONE AND MARROW TRANSPLANT PATIENTS
OSU-14094Samantha JaglowskiA Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
OSU-14099Jeffrey JonesA Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination with ACP-319 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia
OSU-14051Jeffrey JonesA Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
OSU-12142Jeffrey JonesA Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
OSU-12200Jeffrey JonesA Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
OSU-12101Jeffrey JonesA PHASE Ib MULTICENTER DOSE-FINDING AND SAFETY STUDY OF GDC-0199 AND OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
CALGB-150711Jeffrey JonesEmbedded Campanion Study to CALGB-50701
OSU-07068Rebecca KlisovicCorrelative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
OSU-07069Rebecca KlisovicMyeloproliferative Disorder Research Consortium (MPD-RC) Research Tissue Bank
OSU-12163Rebecca KlisovicA Phase IIa, Single-Arm,Open-Label Study of MOR00208,a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL).
OSU-13111Rebecca KlisovicA phase I study of recombinant L-asparaginase encapsulated in erythrocytes (ERYASP) in combination with the CALGB regimen during induction and consolidation phases for frontline therapy of patients older than 40 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
OSU-13112Rebecca KlisovicMyeloproliferative Disorders-Research Consortium (MPD-RC) MPD-RC Protocol 114 Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis
OSU-13195Rebecca KlisovicA phase II randomized, multicenter study of treatment-free remission in chronic myeloid leukemia in chronic phase(CML-CP) patients who achieve and sustain MR4.5 after switching to nilotinib
OSU-06020Eric KrautAn Evaluation of Qualitative Platelet Disorders in Patients with Inherited Disorders of Coagulation.
OSU-1997CO194David LucasTHE OSUCCC HEMATOLOGIC MALIGNANCY BIOREPOSITORY
OSU-0025David LucasDrug Sensitivity & Apoptosis Studies in Hematologic Malignancies
OSU-12095Kami MaddocksA Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia
OSU-11179Kami MaddocksA Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
OSU-13027Kami MaddocksA Phase I Study of BKM120 and Rituximab in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
OSU-14111Kami MaddocksA Phase 1b, Multicenter, Open-label Study of 2 Dosing Regimens of ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
ECOG-E1412Kami MaddocksRandomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
CALGB-211006Guido MarcucciEmbedded Companion to CALGB-11002
CALGB-361006Guido MarcucciEmbedded Companion to CALGB-11001
CALGB-21003Guido MarcucciEmbedded Companion to CALGB-11001
CALGB-21101Guido MarcucciEmbedded Companion to CALGB-11002
CALGB-361101Guido MarcucciEmbedded Companion to CALGB-11002
CALGB-60706Guido MarcucciEmbeded Campanion Study to CALGB 10603
OSU-12002Mitch PhelpsA PROSPECTIVE, DOUBLE-BLINDED, OBSERVATIONAL CLINICAL COHORT STUDY OF THE ASSOCIATION BETWEEN TACROLIMUS EXPOSURE AND CYP3A4, CYP3A5 GENOTYPES IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
OSU-06083Christoph PlassThe Identification of Predisposing Genes in Chronic Lymphocytic Leukemia (CLL).
OSU-05075Pierluigi PorcuA Retrospective Analysis of Clinical Presentation and Therapeutic Outcomes in T/NK-cell Lymphomas at the OSUCCC as a Benchmark for Future Translational Studies, Clinical Trial Design and Prediction of Accrual.
OSU-09073Pierluigi PorcuComputer-aided Clinical Image Analysis for Cutaneous Lymphomas
OSU-13015Pierluigi PorcuA randomized, double-blind, placebo-controlled, phase 3 study of CH-P and brentuximab vedotin versus CHOP in the front-line treatment of patients with CD30-positive mature T-cell lymphomas
OSU-12197Pierluigi PorcuOpen-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
OSU-14003Ashley RoskoA Phase 1b / 2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
OSU-14007Ashley RoskoRetrospective Review: Biomarkers of Frailty Assessment in Myeloma Patients
BMT-CTN1102Sumithira VasuA Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
BMT-CTN1202Sumithira VasuProspective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
OSU-11066Sumithira VasuKIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
OSU-12097Sumithira VasuA multicenter safety study of unlicensed investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
BMTCTN-1101Sumithira VasuA Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
OSU-12091Sumithira VasuA PHASE 2, CONTROLLED TRIAL, OF A SINGLE PROHEMA-CB UNIT (EX VIVO MODULATED HUMAN CORD BLOOD CELLS) AS PART OF A DOUBLE UMBILICAL CORD BLOOD TRANSPLANT FOLLOWING MYELOABLATIVE OR REDUCED INTENSITY CONDITIONING FOR PATIENTS AGE 15-65 YEARS WITH HEMATOLOGIC MALIGNANCIES
AMC-080Sumithira VasuAllogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
OSU-11130Alison WalkerPhase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia
OSU-11186Alison WalkerPhase I Study of the Combination of Bortezomib and Sorafenib followed by Decitabine in Elderly Patients with Acute Myeloid Leukemia
OSU-11021Alison WalkerResearch database for undiagnosed cytopenias.
OSU-12234Katherine WalshRandomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) (A New York Cancer Consortium Study)
OSU-13031Jennifer WoyachA Phase II Study of MOR00208 in Combination with Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients with Untreated CLL/SLL/PLL
ALLIANCE-A041202Jennifer WoyachA Randomized Phase III Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (¡Ý 65 Years Of Age) with Chronic Lymphocytic Leukemia (CLL)

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu